Skip to main content

Table 2 Key secondary endpoints: rates of CDAI and SDAI LDA and remission, ACR responses, improvements in HAQ-DI (primary analysis set; LOCF imputation)

From: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

  Placebo-etanercept (N = 104) Etanercept-etanercept (N = 106)
CDAI LDA (score ≤10), n (%)   
 Week 2 9 (9.1) 13 (12.3)
 Week 8 16 (15.4) 31 (29.2)
 Week 12 22 (21.2) 27 (25.5)
 Week 24 43 (41.3) 49 (46.2)
CDAI remission (score ≤2.8), n (%)   
 Week 2 1 (1.0) 2 (1.9)
 Week 8 0 (0.0) 3 (2.8)
 Week 12 1 (1.0) 4 (3.8)
 Week 24 4 (3.8) 9 (8.5)
SDAI LDA (score ≤11), n (%)   
 Week 2 8 (8.2) 13 (12.4)
 Week 8 15 (14.4) 32 (30.2)
 Week 12 22 (21.2) 25 (23.6)
 Week 24 41 (39.4) 48 (45.3)
SDAI remission (score ≤3.3), n (%)   
 Week 2 1 (1.0) 1 (1.0)
 Week 8 0 (0.0) 6 (5.7)
 Week 12 2 (1.9) 6 (5.7)
 Week 24 7 (6.7) 11 (10.4)
ACR20 response, n (%)   
 Week 2 15 (14.9) 30 (28.6)
 Week 8 24 (23.1) 53 (50.0)
 Week 12 30 (28.8) 43 (40.6)
 Week 24 48 (46.2) 53 (50.0)
ACR50 response, n (%)   
 Week 2 3 (3.0) 6 (5.7)
 Week 8 5 (4.8) 21 (19.8)
 Week 12 13 (12.5) 22 (20.8)
 Week 24 30 (28.8) 35 (33.0)
ACR70 response, n (%)   
 Week 2 0 (0.0) 2 (1.9)
 Week 8 0 (0.0) 6 (5.7)
 Week 12 1 (1.0) 6 (5.7)
 Week 24 13 (12.5) 17 (16.0)
Change from baseline in HAQ-DI, mean score change (SD)   
 Week 2 −0.09 (0.39) −0.27 (0.43)
 Week 8 −0.21 (0.42) −0.37 (0.47)
 Week 12 −0.20 (0.43) −0.39 (0.54)
 Week 24 −0.45 (0.52) −0.48 (0.58)
  1. CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index; LDA: low disease activity; ACR: American College of Rheumatology; HAQ-DI: Health Assessment Questionnaire Disability Index; LOCF: last observation carried forward; SD: standard deviation.